Carbetocin versus syntometrine in prevention of post-partum hemorrhage following vaginal delivery

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective: To compare the efficacy of a single dose of 100 μg intramuscular carbetocin to a single dose of intramuscular syntometrine (0.5 mg ergometrine and 5IU oxytocin), in preventing post-partum hemorrhage (PPH) in high risk patients following vaginal delivery. Methods: A prospective, randomized controlled study was conducted in a tertiary hospital where 120 pregnant women with risk factors for PPH who delivered vaginally were randomized into two groups: the study group where 100 μg intramuscular carbetocin was administered and the control group, who received intramuscular syntometrine. Outcome measures compared included changes in vital signs, amount of intrapartum blood loss, uterine fundal position, addition of another oxytocic agent, side-effects of the drugs, amount of lochia and hemoglobin drop after 24 hours post-partum. Incidence of PPH or other adverse events were also compared. Results: There were no significant differences in terms of requirement for additional oxytocic agents, time interval to well contracted uterus, blood transfusion requirements, adverse effects or complications. There was a significantly lower mean estimated blood loss in the carbetocin group compared to the syntometrine group (244 ± 114 mL vs 343 ± 143 mL, 95% CI 52-146 mL). There was also a significantly reduced drop in hemoglobin in the carbetocin group compared to the syntometrine group (0.3 ± 0.2 g/dL vs 0.4 ± 0.2 g/dL, 95% CI 0.1-0.2 g/dL). Conclusion: Intramuscular carbetocin may be more effective than intramuscular syntometrine in reducing post-partum blood loss and the drop in hemoglobin level.

Original languageEnglish
Pages (from-to)48-54
Number of pages7
JournalJournal of Obstetrics and Gynaecology Research
Volume35
Issue number1
DOIs
Publication statusPublished - Feb 2009

Fingerprint

Hemorrhage
Oxytocics
Hemoglobins
Ergonovine
Vital Signs
Oxytocin
Drug-Related Side Effects and Adverse Reactions
Tertiary Care Centers
Blood Transfusion
Uterus
Pregnant Women
Outcome Assessment (Health Care)
carbetocin
syntometrine
Control Groups
Incidence

Keywords

  • Blood loss
  • Carbetocin
  • Oxytocic agent
  • Post-partum hemorrhage
  • Syntometrine

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

@article{851d4202e89743c7a448c31f6506f363,
title = "Carbetocin versus syntometrine in prevention of post-partum hemorrhage following vaginal delivery",
abstract = "Objective: To compare the efficacy of a single dose of 100 μg intramuscular carbetocin to a single dose of intramuscular syntometrine (0.5 mg ergometrine and 5IU oxytocin), in preventing post-partum hemorrhage (PPH) in high risk patients following vaginal delivery. Methods: A prospective, randomized controlled study was conducted in a tertiary hospital where 120 pregnant women with risk factors for PPH who delivered vaginally were randomized into two groups: the study group where 100 μg intramuscular carbetocin was administered and the control group, who received intramuscular syntometrine. Outcome measures compared included changes in vital signs, amount of intrapartum blood loss, uterine fundal position, addition of another oxytocic agent, side-effects of the drugs, amount of lochia and hemoglobin drop after 24 hours post-partum. Incidence of PPH or other adverse events were also compared. Results: There were no significant differences in terms of requirement for additional oxytocic agents, time interval to well contracted uterus, blood transfusion requirements, adverse effects or complications. There was a significantly lower mean estimated blood loss in the carbetocin group compared to the syntometrine group (244 ± 114 mL vs 343 ± 143 mL, 95{\%} CI 52-146 mL). There was also a significantly reduced drop in hemoglobin in the carbetocin group compared to the syntometrine group (0.3 ± 0.2 g/dL vs 0.4 ± 0.2 g/dL, 95{\%} CI 0.1-0.2 g/dL). Conclusion: Intramuscular carbetocin may be more effective than intramuscular syntometrine in reducing post-partum blood loss and the drop in hemoglobin level.",
keywords = "Blood loss, Carbetocin, Oxytocic agent, Post-partum hemorrhage, Syntometrine",
author = "Kampan, {Nirmala @ Chandralega} and Zainuddin, {Ani Amelia} and {Abdul Ghani}, {Nur Azurah} and {Syed Zakaria}, {Syed Zulkifli} and Jamil, {Mohd Abdul}",
year = "2009",
month = "2",
doi = "10.1111/j.1447-0756.2008.00829.x",
language = "English",
volume = "35",
pages = "48--54",
journal = "Asia-Oceania Journal of Obstetrics and Gynaecology",
issn = "1341-8076",
publisher = "Blackwell Publishing Asia",
number = "1",

}

TY - JOUR

T1 - Carbetocin versus syntometrine in prevention of post-partum hemorrhage following vaginal delivery

AU - Kampan, Nirmala @ Chandralega

AU - Zainuddin, Ani Amelia

AU - Abdul Ghani, Nur Azurah

AU - Syed Zakaria, Syed Zulkifli

AU - Jamil, Mohd Abdul

PY - 2009/2

Y1 - 2009/2

N2 - Objective: To compare the efficacy of a single dose of 100 μg intramuscular carbetocin to a single dose of intramuscular syntometrine (0.5 mg ergometrine and 5IU oxytocin), in preventing post-partum hemorrhage (PPH) in high risk patients following vaginal delivery. Methods: A prospective, randomized controlled study was conducted in a tertiary hospital where 120 pregnant women with risk factors for PPH who delivered vaginally were randomized into two groups: the study group where 100 μg intramuscular carbetocin was administered and the control group, who received intramuscular syntometrine. Outcome measures compared included changes in vital signs, amount of intrapartum blood loss, uterine fundal position, addition of another oxytocic agent, side-effects of the drugs, amount of lochia and hemoglobin drop after 24 hours post-partum. Incidence of PPH or other adverse events were also compared. Results: There were no significant differences in terms of requirement for additional oxytocic agents, time interval to well contracted uterus, blood transfusion requirements, adverse effects or complications. There was a significantly lower mean estimated blood loss in the carbetocin group compared to the syntometrine group (244 ± 114 mL vs 343 ± 143 mL, 95% CI 52-146 mL). There was also a significantly reduced drop in hemoglobin in the carbetocin group compared to the syntometrine group (0.3 ± 0.2 g/dL vs 0.4 ± 0.2 g/dL, 95% CI 0.1-0.2 g/dL). Conclusion: Intramuscular carbetocin may be more effective than intramuscular syntometrine in reducing post-partum blood loss and the drop in hemoglobin level.

AB - Objective: To compare the efficacy of a single dose of 100 μg intramuscular carbetocin to a single dose of intramuscular syntometrine (0.5 mg ergometrine and 5IU oxytocin), in preventing post-partum hemorrhage (PPH) in high risk patients following vaginal delivery. Methods: A prospective, randomized controlled study was conducted in a tertiary hospital where 120 pregnant women with risk factors for PPH who delivered vaginally were randomized into two groups: the study group where 100 μg intramuscular carbetocin was administered and the control group, who received intramuscular syntometrine. Outcome measures compared included changes in vital signs, amount of intrapartum blood loss, uterine fundal position, addition of another oxytocic agent, side-effects of the drugs, amount of lochia and hemoglobin drop after 24 hours post-partum. Incidence of PPH or other adverse events were also compared. Results: There were no significant differences in terms of requirement for additional oxytocic agents, time interval to well contracted uterus, blood transfusion requirements, adverse effects or complications. There was a significantly lower mean estimated blood loss in the carbetocin group compared to the syntometrine group (244 ± 114 mL vs 343 ± 143 mL, 95% CI 52-146 mL). There was also a significantly reduced drop in hemoglobin in the carbetocin group compared to the syntometrine group (0.3 ± 0.2 g/dL vs 0.4 ± 0.2 g/dL, 95% CI 0.1-0.2 g/dL). Conclusion: Intramuscular carbetocin may be more effective than intramuscular syntometrine in reducing post-partum blood loss and the drop in hemoglobin level.

KW - Blood loss

KW - Carbetocin

KW - Oxytocic agent

KW - Post-partum hemorrhage

KW - Syntometrine

UR - http://www.scopus.com/inward/record.url?scp=58849106406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58849106406&partnerID=8YFLogxK

U2 - 10.1111/j.1447-0756.2008.00829.x

DO - 10.1111/j.1447-0756.2008.00829.x

M3 - Article

C2 - 19215547

AN - SCOPUS:58849106406

VL - 35

SP - 48

EP - 54

JO - Asia-Oceania Journal of Obstetrics and Gynaecology

JF - Asia-Oceania Journal of Obstetrics and Gynaecology

SN - 1341-8076

IS - 1

ER -